Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

EQS-News: MorphoSys Reports Preliminary Q3 2023 Monjuvi U.S. Sales and Gross Margin, and Updates Financial Guidance for 2023: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: MorphoSys Reports Preliminary Q3 2023 Monjuvi U.S. Sales and Gross Margin, and Updates Financial Guidance for 2023
EQS-News: MorphoSys Reports Preliminary Q3 2023 Monjuvi U.S. Sales and Gross Margin, and Updates Financial Guidance for 2023
EQS-Adhoc: Ad hoc: MorphoSys AG Reports Preliminary Q3 2023 Monjuvi U.S. Sales and Gross Margin, and Updates Financial Guidance for 2023: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-Adhoc: Ad hoc: MorphoSys AG Reports Preliminary Q3 2023 Monjuvi U.S. Sales and Gross Margin, and Updates Financial Guidance for 2023
EQS-Adhoc: Ad hoc: MorphoSys AG Reports Preliminary Q3 2023 Monjuvi U.S. Sales and Gross Margin, and Updates Financial Guidance for 2023
EQS-Adhoc: Ad hoc: MorphoSys AG Reports Preliminary Q3 2023 Monjuvi U.S. Sales and Gross Margin, and Updates Financial Guidance for 2023: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-Adhoc: Ad hoc: MorphoSys AG Reports Preliminary Q3 2023 Monjuvi U.S. Sales and Gross Margin, and Updates Financial Guidance for 2023
EQS-Adhoc: Ad hoc: MorphoSys AG Reports Preliminary Q3 2023 Monjuvi U.S. Sales and Gross Margin, and Updates Financial Guidance for 2023
Why LianBio Stock Is Skyrocketing Today: https://g.foolcdn.com/editorial/images/752037/scientists-asian.jpg
Why LianBio Stock Is Skyrocketing Today

Shares of LianBio (NASDAQ: LIAN) were skyrocketing 132.4% higher as of 11:11 a.m. ET on Tuesday. The huge gain came after the company announced that it entered into an agreement to hand over

Abbott Laboratories May Soon Launch a Game-Changing New Device in the U.S.: https://g.foolcdn.com/editorial/images/751839/a-doctor-looking-at-a-tablet-with-another-person.jpg
Abbott Laboratories May Soon Launch a Game-Changing New Device in the U.S.

Abbott Laboratories (NYSE: ABT) has been a disappointing investment in recent years. While COVID-19 testing gave the business a boost, this has largely been a slow-growing company. And since 2020

The Best Stocks to Invest $5,000 In Right Now: https://g.foolcdn.com/editorial/images/751878/gettyimages-103919680.jpg
The Best Stocks to Invest $5,000 In Right Now

Bear markets and bull markets come and go, so it's best to avoid building your portfolio around one specific market phase. Instead, pick up shares of companies with potential to grow your wealth

The Best Stocks to Invest $5,000 In Right Now: https://g.foolcdn.com/editorial/images/751878/gettyimages-103919680.jpg
The Best Stocks to Invest $5,000 In Right Now

Bear markets and bull markets come and go, so it's best to avoid building your portfolio around one specific market phase. Instead, pick up shares of companies with potential to grow your wealth

The Best Stocks to Invest $5,000 In Right Now: https://g.foolcdn.com/editorial/images/751878/gettyimages-103919680.jpg
The Best Stocks to Invest $5,000 In Right Now

Bear markets and bull markets come and go, so it's best to avoid building your portfolio around one specific market phase. Instead, pick up shares of companies with potential to grow your wealth

Why CymaBay Therapeutics Stock Rocketed Nearly 8% Higher Today: https://g.foolcdn.com/editorial/images/751969/person-in-a-lab-looking-through-a-microscope.jpg
Why CymaBay Therapeutics Stock Rocketed Nearly 8% Higher Today

Hardly for the first time this year, biotech CymaBay Therapeutics (NASDAQ: CBAY) had a winning day on the market Monday. Following the news that its leading drug candidate had been granted an

Why Revolution Medicines Stock Is Crashing Today: https://g.foolcdn.com/editorial/images/751899/scientist-with-head-down.jpg
Why Revolution Medicines Stock Is Crashing Today

Shares of Revolution Medicines (NASDAQ: RVMD) were crashing 42.5% lower as of 11:13 a.m. ET on Monday. The steep decline came after the oncology company presented results on Sunday for RMC-6236 from

3 Stocks Cathie Wood Is Buying That Should Be on Your List Too: https://g.foolcdn.com/editorial/images/751770/dna-genetic-sequencing-biotech-1.jpg
3 Stocks Cathie Wood Is Buying That Should Be on Your List Too

Cathie Woods, through her various ARK funds, has been scooping up shares of Intellia Therapeutics (NASDAQ: NTLA), Block (NYSE: SQ), and Ginkgo Bioworks (NYSE: DNA) lately. All three stocks have

3 Unstoppable Stocks to Buy Sooner Rather Than Later: https://g.foolcdn.com/editorial/images/751591/scientists-happy.jpg
3 Unstoppable Stocks to Buy Sooner Rather Than Later

Some stocks have the "it" factor. They've got such tremendous growth prospects that investors want to add them to their portfolios without any hesitation.

Three Motley Fool investors think they've

3 Unstoppable Stocks to Buy Sooner Rather Than Later: https://g.foolcdn.com/editorial/images/751591/scientists-happy.jpg
3 Unstoppable Stocks to Buy Sooner Rather Than Later

Some stocks have the "it" factor. They've got such tremendous growth prospects that investors want to add them to their portfolios without any hesitation.

Three Motley Fool investors think they've

3 Unstoppable Stocks to Buy Sooner Rather Than Later: https://g.foolcdn.com/editorial/images/751591/scientists-happy.jpg
3 Unstoppable Stocks to Buy Sooner Rather Than Later

Some stocks have the "it" factor. They've got such tremendous growth prospects that investors want to add them to their portfolios without any hesitation.

Three Motley Fool investors think they've

Pfizer Just Announced Layoffs. Should You Still Buy the Stock?: https://g.foolcdn.com/editorial/images/751579/investor-considers-papers-at-a-cafe.jpg
Pfizer Just Announced Layoffs. Should You Still Buy the Stock?

On October 13, Pfizer (NYSE: PFE) served up a platter of bad news for investors. Aside from lowering its estimates for sales of its jab and its antiviral pill for COVID, the company reported that

Pfizer Just Announced Layoffs. Should You Still Buy the Stock?: https://g.foolcdn.com/editorial/images/751579/investor-considers-papers-at-a-cafe.jpg
Pfizer Just Announced Layoffs. Should You Still Buy the Stock?

On October 13, Pfizer (NYSE: PFE) served up a platter of bad news for investors. Aside from lowering its estimates for sales of its jab and its antiviral pill for COVID, the company reported that

3 Safe Dividend Stocks to Beat Inflation: https://g.foolcdn.com/editorial/images/751608/chain-and-padlock-wrapped-around-stack-of-100-dollar-bills-cash-money-locked-up.jpeg
3 Safe Dividend Stocks to Beat Inflation

Like it or not, inflation remains higher than Americans have been accustomed to, and the impacts of last year's price surge have not gone away. As of September, inflation as measured by the Consumer

Which Is the Better Long-Term Hold for Investors: Pfizer or Roche?: https://g.foolcdn.com/editorial/images/751646/jazz-pharma.jpg
Which Is the Better Long-Term Hold for Investors: Pfizer or Roche?

Pfizer (NYSE: PFE) and Roche (OTC: RHHBY) have disappointed investors this year. Pfizer's shares have dropped more than 39% this year, and it's trading near its 52-week low. Roche has seen its stock

Which Is the Better Long-Term Hold for Investors: Pfizer or Roche?: https://g.foolcdn.com/editorial/images/751646/jazz-pharma.jpg
Which Is the Better Long-Term Hold for Investors: Pfizer or Roche?

Pfizer (NYSE: PFE) and Roche (OTC: RHHBY) have disappointed investors this year. Pfizer's shares have dropped more than 39% this year, and it's trading near its 52-week low. Roche has seen its stock

Is Pfizer a Bad News Buy Right Now?: https://g.foolcdn.com/editorial/images/751705/gettyimages-1203044156.jpg
Is Pfizer a Bad News Buy Right Now?

Pfizer (NYSE: PFE) last year brought in record sales of more than $100 billion thanks to its dominance in the coronavirus prevention and treatment markets. The company sells the top vaccine

Is Pfizer a Bad News Buy Right Now?: https://g.foolcdn.com/editorial/images/751705/gettyimages-1203044156.jpg
Is Pfizer a Bad News Buy Right Now?

Pfizer (NYSE: PFE) last year brought in record sales of more than $100 billion thanks to its dominance in the coronavirus prevention and treatment markets. The company sells the top vaccine

Why Knight-Swift Transportation Stock Popped Today: https://g.foolcdn.com/editorial/images/751717/truck-warehouse-loading-dock.jpg
Why Knight-Swift Transportation Stock Popped Today

Shares of Knight-Swift Transportation (NYSE: KNX) were moving higher today after the diversified transportation company topped analyst estimates in its third-quarter earnings report.

As of 11:27

3 Under-the-Radar Biotech Stocks to Buy in 2023: https://g.foolcdn.com/editorial/images/751195/dnaphoto.jpg
3 Under-the-Radar Biotech Stocks to Buy in 2023

Biotech stocks have been beaten down in 2023, with the sector off nearly 4% this year while the S&P 500 is up more than 15%. But some of the larger, better known biotech stocks have thrived --

3 Under-the-Radar Biotech Stocks to Buy in 2023: https://g.foolcdn.com/editorial/images/751195/dnaphoto.jpg
3 Under-the-Radar Biotech Stocks to Buy in 2023

Biotech stocks have been beaten down in 2023, with the sector off nearly 4% this year while the S&P 500 is up more than 15%. But some of the larger, better known biotech stocks have thrived --

3 Under-the-Radar Biotech Stocks to Buy in 2023: https://g.foolcdn.com/editorial/images/751195/dnaphoto.jpg
3 Under-the-Radar Biotech Stocks to Buy in 2023

Biotech stocks have been beaten down in 2023, with the sector off nearly 4% this year while the S&P 500 is up more than 15%. But some of the larger, better known biotech stocks have thrived --